Murray Norris
Children's Cancer Institute, NSW, Australia
- This delegate is presenting an abstract at this event.
Murray Norris is Director of the Centre for Childhood Cancer Research at the University of New South Wales and Deputy Director of the Children’s Cancer Institute Australia. He obtained his bachelor’s degree in biochemistry from the Australian National University and his PhD in 1989 from the University of New South Wales. His lab focusses on developing novel therapies for childhood cancers and he has been responsible for developing and implementing unique technology enabling the early prediction of relapse in children with acute lymphoblastic leukaemia. From 2016-2018 he served as President of the International Advances in Neuroblastoma Research Association and has a strong interest in elucidating the molecular mechanisms behind MYCN-driven tumourigenesis.
Presentations this author is a contributor to:
MYCN coordinately regulates the entire polyamine pathway to maintain high polyamine levels in neuroblastoma (#116)
2:15 PM
Laura Gamble
Afternoon Tea/Poster Session
Discovery of a small molecule TUBB3/βIII-tubulin modulator in lung cancer (#126)
2:15 PM
Felicity Kao
Afternoon Tea/Poster Session
TESTING HIGH RISK CHILDHOOD CANCER PATIENT CELLS IN VITRO FOR POTENTIAL NEW DRUG TREATMENTS (#101)
2:15 PM
Greg M Arndt
Afternoon Tea/Poster Session
THE ACRF DRUG DISCOVERY CENTRE: AN EARLY-STAGE DRUG DISCOVERY SERVICE (#132)
2:15 PM
Anna Mariana
Afternoon Tea/Poster Session
A novel anti-cancer agent that sensitizes neuroblastoma cells to chemotherapy and targets cellular metabolism (#115)
2:15 PM
Claudia Flemming
Afternoon Tea/Poster Session
CBL0137, a novel NFkB suppressor and p53 activator, is highly effective in two independent pre-clinical mouse models of neuroblastoma (#136)
2:15 PM
Jayne Murray
Afternoon Tea/Poster Session
M606, a novel small molecule inhibitor of MYCN oncoprotein (#162)
2:15 PM
Chengyuan Xue
Afternoon Tea/Poster Session